(Q41029387)

English

Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

scientific article published on 28 August 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

juvenile rheumatoid arthritis

1 reference

based on heuristic

inferred from title

activation syndrome

1 reference

based on heuristic

inferred from title

macrophage activation syndrome

1 reference

based on heuristic

inferred from title

Nicolino Ruperto

7

object named as

Nicolino Ruperto

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

author name string

Alexei A Grom

1

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Norman T Ilowite

2

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Virginia Pascual

3

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Hermine I Brunner

4

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Alberto Martini

5

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Daniel Lovell

6

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group

8

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Karolynn Leon

9

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Karine Lheritier

10

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Ken Abrams

11

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

publication date

28 August 2015

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

68

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

218-228

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Macrophage activation syndrome and cytokine-directed therapies

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis [...]

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Interleukin-18 and the pathogenesis of inflammatory diseases

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Genetic defects in cytolysis in macrophage activation syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FART.39407

21 January 2018

Identifiers

10.1002/ART.39407

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41029387&oldid=2093340637"